NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Tardive Dyskinesia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 1005828
出版日期 內容資訊 英文 117 Pages
商品交期: 2-3個工作天內
遲發性運動障礙治療的全球市場:成長,趨勢,COVID-19的影響,預測(2021年∼2026年) Tardive Dyskinesia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
出版日期: 2021年04月21日內容資訊: 英文 117 Pages




第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場原動力
    • 神經疾病的增加
    • 抗精神病藥的處方增加
    • 思覺失調症患者的增加
  • 市場阻礙因素
    • 藥的副作用
  • 波特的五力分析

第5章 市場區隔

  • 各疾病
    • 運動遲緩
    • 過敏症
  • 各類藥物
    • 多巴胺乾涸藥
    • VMAT2抑制劑
    • GABA受體激動劑
    • 抗膽鹼能藥物苯海索
  • 各終端用戶
    • 醫院
    • 診療所
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區

第6章 競爭情形

  • 企業簡介
    • Teva Pharmaceutical Industries Ltd
    • Neurocrine Biosciences, Inc
    • Sun Pharmaceutical Industries Ltd
    • SteriMax Inc.
    • Adamas Pharmaceuticals, Inc
    • Sanis
    • AbbVie Inc.

第7章 市場機會及趨勢


Product Code: 68912

The Tardive Dyskinesia Treatment Market is expected to register a CAGR of 4% during the forecast period. This is attributing to growing number of Schizophrenia Patients, rising incidences of neurological disorders. With prolonged use of antipsychotic drugs by schizophrenia patients, the chances of patients suffering from tardive dyskinesia are high. Thus high risk associated with growing number of antipsychotic drugs leading to promote the growth of the overall market. Tardive dyskinesia is an involuntary neurological movement disorder wherein there is an uncontrolled movement of body parts such as eyeballs, lips, and tongue. Moreover, the strong clinical trial pipeline for the treatment of tardive dyskinesia by several manufacturing companies is also boosting the market.

However, side effects of drugs lack awareness about the disorder and many undiagnosed cases may restrain the market to a certain extent.

Key Market Trends

VMAT Inhibitor is Expected to Witness a healthy Growth in Future

VMAT is expected to witness healthy growth in the future attributed to a growing number of neurological disorders and growing antipsychotic prescriptions. Several product approvals in VMAT inhibitors are promoting the growth of the market. For instance, in 2017 Neurocine biosciences got approval from the Food and Drug Administration (FDA) for a drug Valbenazine marketed under Ingrezza for the treatment of Tardive dyskinesia. In addition, Teva Pharmaceuticals drug name Austedo also gets approval. This results in driving the Tardive dyskinesia Treatment market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the global Tardive Dyskinesia Treatment Market due to the increasing aging population, high prevalence of schizophrenia, increasing awareness, increasing healthcare expenditure and the presence of well-established healthcare infrastructure. As growing aging population will be leading to many diseases related to neurological for which this population has to take antipsychiatric drugs. Thus these populations are more prone to develop these diseases. Moreover, targeted patient pools such as populations treated with schizophrenia and bipolar disorder in this region are also associated with this disorder, hence promotes the growth of the tardive dyskinesia treatment market in this region.

Competitive Landscape

The Tardive Dyskinesia Treatment Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Teva Pharmaceutical Industries Ltd Neurocrine Biosciences, Inc, Sun Pharmaceutical Industries Ltd, SteriMax Inc., Lannett Co Inc, Sanis, and Allergan

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Number of Neurological Disorder
    • 4.2.2 Growing Antipsychotic Prescriptions
    • 4.2.3 Rising Schizophrenia Patients
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Disorder
    • 5.1.1 Bradykinesia
    • 5.1.2 Hyperkinesia
  • 5.2 By Drug Class
    • 5.2.1 Dopamine-Depleting Medications
    • 5.2.2 VMAT2 Inhibitors
    • 5.2.3 GABA Receptor Agonist Medications
    • 5.2.4 Anticholinergic Medications Trihexyphenidyl
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Clinical
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Rest of the World


  • 6.1 Company Profiles
    • 6.1.1 Teva Pharmaceutical Industries Ltd
    • 6.1.2 Neurocrine Biosciences, Inc
    • 6.1.3 Sun Pharmaceutical Industries Ltd
    • 6.1.4 SteriMax Inc.
    • 6.1.5 Adamas Pharmaceuticals, Inc
    • 6.1.6 Sanis
    • 6.1.7 AbbVie Inc.